Helicobacter pylori, the bacterium known to cause peptic ulcers, is also the primary cause of gastric cancer, which is a leading cancer killer globally.
A large clinical trial at seven sites across Latin America has now found that a standard three-drug regimen for treating H. pylori is more effective, at least in the population studied, than either of two four-drug regimens that proved superior in studies in Europe and Asia.
"This study turns recent literature a bit on its head," says study coauthor William D. Chey, M.D., of the University of Michigan. "Specifically, virtually all other randomized, controlled trials that have tested the four-drug therapy, either sequentially over ten days or concomitantly over five days, have found it superior."
Click "source" for entire article.
"14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial." (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60825-8/abstract)